Aimmune Therapeutics Inc (NASDAQ:AIMT) had its Outperform rating reiterated by Wedbush with a $76.00 price target

Analyst Ratings For Aimmune Therapeutics Inc (NASDAQ:AIMT)

Story continues below

Today, Wedbush reiterated its Outperform rating on Aimmune Therapeutics Inc (NASDAQ:AIMT) with a price target of $76.00.

There are 5 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Aimmune Therapeutics Inc (NASDAQ:AIMT) is Buy with a consensus target price of $48.5729 per share, a potential 116.84% upside.

Some recent analyst ratings include

  • 3/19/2019-Aimmune Therapeutics Inc (NASDAQ:AIMT) had its Outperform rating reiterated by Wedbush with a $76.00 price target
  • 1/15/2019-Aimmune Therapeutics Inc (NASDAQ:AIMT) had its Buy rating reiterated by Credit Suisse Group with a $40.00 price target
  • 5/18/2018-Aimmune Therapeutics Inc (NASDAQ:AIMT) has coverage initiated with a Overweight rating and $30.01 price target
  • On 11/19/2018 Jayson Donald Alexander Dallas, Insider, bought 3,650 with an average share price of $27.56 per share and the total transaction amounting to $100,594.00.
  • On 6/13/2018 Eric Bjerkholt, CFO, bought 1,600 with an average share price of $30.41 per share and the total transaction amounting to $48,656.00.
  • On 6/11/2018 Stephen George Dilly, CEO, sold 29,457 with an average share price of $30.83 per share and the total transaction amounting to $908,159.31.
  • On 6/8/2018 Stephen George Dilly, Insider, sold 105,169 with an average share price of $30.92 per share and the total transaction amounting to $3,251,825.48.
  • On 6/5/2018 Stephen George Dilly, Insider, sold 165,374 with an average share price of $32.14 per share and the total transaction amounting to $5,315,120.36.
  • On 6/1/2018 Stephen George Dilly, Insider, sold 61,197 with an average share price of $32.62 per share and the total transaction amounting to $1,996,246.14.
  • On 5/22/2018 Douglas T. Sheehy, Insider, sold 3,296 with an average share price of $33.00 per share and the total transaction amounting to $108,768.00.

About Aimmune Therapeutics Inc (NASDAQ:AIMT)
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Recent Trading Activity for Aimmune Therapeutics Inc (NASDAQ:AIMT)
Shares of Aimmune Therapeutics Inc closed the previous trading session at 22,40 −1,06 4,52 % with 23 shares trading hands.

An ad to help with our costs